Investor Alert: Soleno Therapeutics Inc. (SLNO)

Soleno Therapeutics Inc. (SLNO) Investment Losses

The White Law Group is investigating potential securities claims involving broker-dealers who may have unsuitably recommended Soleno Therapeutics Inc. (NASDAQ: SLNO) to investors.

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of rare diseases. Like many early- and mid-stage biotechnology companies, Soleno’s business model depends heavily on successful research and development, regulatory approvals, and the ability to raise capital through public offerings.

Significant Stock Decline

According to Yahoo Finance, as of December 1, 2025, the share price of Soleno Therapeutics Inc. is down more than 98%, resulting in substantial losses for investors who purchased the stock at higher prices. Significant price declines of this magnitude often raise questions about risk disclosures, suitability, and the recommendations made by financial advisors.

Risks of Pharmaceutical and Biotech Investments

Pharmaceutical and biotechnology investments typically involve a high degree of risk, particularly for retail investors. These companies often spend years and significant capital on clinical trials that must meet specific endpoints. When trials fail, data disappoints, or regulatory milestones are delayed or denied, stock prices can decline sharply.

Broker-dealers are required to:

• Conduct reasonable due diligence on investments they recommend
• Fully disclose material risks to investors
• Ensure that recommendations are suitable based on an investor’s age, risk tolerance, financial objectives, and overall investment profile

When these obligations are not met, brokerage firms and financial advisors may be held responsible for investor losses.

Soleno Therapeutics Underwritten Offerings

Soleno Therapeutics has reportedly raised capital through several underwritten public offerings, which may be relevant to investors who purchased shares around offering periods. These offerings include:

• July 2025 Offering – Approximately $200 Million
  • Joint book-running managers included Goldman Sachs & Co. LLC, Guggenheim Securities, TD Cowen, Cantor Fitzgerald, and Oppenheimer & Co.
• 2023 Offering
  • Led by Guggenheim Securities
• Earlier Public Offerings
  • Oppenheimer & Co. served as lead book-running manager

Investors who purchased shares in or around these offerings based on broker recommendations should carefully review whether the risks were properly disclosed and whether the investment was suitable.

FINRA Arbitration and Investor Recovery Options

Investors who believe they were harmed by unsuitable recommendations, misrepresentations, or omissions related to Soleno Therapeutics may be able to pursue recovery through FINRA arbitration.

FINRA arbitration is the primary dispute resolution forum for claims against brokerage firms and registered representatives. These claims often involve allegations such as:

• Unsuitable investment recommendations
• Failure to disclose material risks
• Overconcentration in speculative or high-risk securities
• Negligent supervision by brokerage firms

Arbitration is generally faster and more cost-effective than court litigation, and investors may be able to recover damages for losses caused by broker misconduct.

Filing a Complaint Against Your Brokerage Firm

If you are concerned about losses related to Soleno Therapeutics Inc. (SLNO), you may be able to file a claim against your brokerage firm through FINRA arbitration.

The securities attorneys at The White Law Group offer free consultations to evaluate potential claims.

Call 1-888-637-5510 to speak with an attorney about your investment losses.

The White Law Group is a national securities fraud, securities arbitration, and investor protection law firm with offices in Chicago, Illinois and Seattle, Washington. The firm represents investors nationwide in claims against brokerage firms and financial advisors.

For more information, visit www.WhiteSecuritiesLaw.com.

Frequently Asked Questions (FAQs)

1. Can I recover losses from investing in Soleno Therapeutics stock?

Possibly. If your broker or financial advisor recommended Soleno Therapeutics without adequately disclosing the risks or if the investment was unsuitable for your financial profile, you may be able to seek recovery through FINRA arbitration.

2. What makes a biotech stock recommendation unsuitable?

Biotech stocks may be unsuitable if they are recommended to conservative or income-focused investors, if they result in overconcentration in speculative securities, or if the broker fails to explain the high risk of clinical trial failure and stock volatility.

3. How long do I have to file a FINRA arbitration claim?

FINRA generally imposes a six-year eligibility rule from the date of the events giving rise to the claim. However, shorter statutes of limitation may apply depending on the circumstances, so investors should consult an attorney as soon as possible.